NASDAQ:ADAP - Adaptimmune Therapeutics Stock Price, Forecast & News

Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."

Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) posted its quarterly earnings data on Wednesday, November, 6th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by $0.03. The biotechnology company earned $0.24 million during the quarter, compared to the consensus estimate of $7 million. View Adaptimmune Therapeutics' Earnings History.

Adaptimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Adaptimmune Therapeutics.

7 brokers have issued 1 year price targets for Adaptimmune Therapeutics' shares. Their forecasts range from $4.15 to $8.00. On average, they expect Adaptimmune Therapeutics' share price to reach $6.03 in the next twelve months. This suggests a possible upside of 73.8% from the stock's current price. View Analyst Price Targets for Adaptimmune Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adaptimmune Therapeutics.

Media headlines about ADAP stock have trended extremely negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Adaptimmune Therapeutics earned a daily sentiment score of -4.4 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Adaptimmune Therapeutics.

Adaptimmune Therapeutics saw a decrease in short interest in the month of February. As of February 14th, there was short interest totalling 584,100 shares, a decrease of 66.4% from the January 30th total of 1,740,000 shares. Based on an average daily trading volume, of 1,950,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.7% of the shares of the stock are sold short. View Adaptimmune Therapeutics' Current Options Chain.

Some companies that are related to Adaptimmune Therapeutics include Regenxbio (RGNX), Cortexyme (CRTX), SpringWorks Therapeutics (SWTX), Coherus Biosciences (CHRS), Beam Therapeutics (BEAM), NanoString Technologies (NSTG), Editas Medicine (EDIT), Orchard Therapeutics (ORTX), I-Mab (BDTX), Twist Bioscience (TWST), BAVARIAN NORDIC/S (BVNRY), Krystal Biotech (KRYS), DBV TECHNOLOGIE/S (DBVT), Mesoblast (MESO) and Aerie Pharmaceuticals (AERI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Second Sight Medical Products (EYES), Brainstorm Cell Therapeutics (BCLI), BlackRock (BLK), Shopify (SHOP), Cara Therapeutics (CARA), Chipotle Mexican Grill (CMG) and Micron Technology (MU).

(ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Adaptimmune Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (4.10%), Renaissance Technologies LLC (1.40%), Man Group plc (1.04%), Polygon Management Ltd. (0.82%), Geode Capital Management LLC (0.09%) and Partnervest Advisory Services LLC (0.03%). Company insiders that own Adaptimmune Therapeutics stock include Adrian Rawcliffe, Ali Behbahani, David M Mott, Elliot Norry, Enterprise Associates 14 New, Gwendolyn Knowlt Binder-Scholl, James Noble, John Lunger, Lawrence M Alleva, Orbimed Advisors Llc, Peter A Thompson, Peter W Sonsini, Rafael Amado, Ravi Viswanathan and William C Bertrand, Jr. View Institutional Ownership Trends for Adaptimmune Therapeutics.

ADAP stock was sold by a variety of institutional investors in the last quarter, including Man Group plc and Marshall Wace LLP. Company insiders that have sold Adaptimmune Therapeutics company stock in the last year include Adrian Rawcliffe, Elliot Norry, James Noble, John Lunger, Rafael Amado and William C Bertrand, Jr. View Insider Buying and Selling for Adaptimmune Therapeutics.

ADAP stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Polygon Management Ltd., Baillie Gifford & Co., Partnervest Advisory Services LLC, Geode Capital Management LLC and Raymond James & Associates. Company insiders that have bought Adaptimmune Therapeutics stock in the last two years include Ali Behbahani, David M Mott, Enterprise Associates 14 New, Lawrence M Alleva, Peter W Sonsini and Ravi Viswanathan. View Insider Buying and Selling for Adaptimmune Therapeutics.

Shares of ADAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADAP stock can currently be purchased for approximately $3.47.

Adaptimmune Therapeutics has a market capitalization of $363.27 million and generates $59.51 million in revenue each year. The biotechnology company earns $-95,510,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis. Adaptimmune Therapeutics employs 406 workers across the globe.View Additional Information About Adaptimmune Therapeutics.

The official website for Adaptimmune Therapeutics is http://www.adaptimmune.com/.

Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company can be reached via phone at 44-12-3543-0000 or via email at [email protected]